Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.

Hdl Handle:
http://hdl.handle.net/10144/322390
Title:
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Authors:
Rangaka, Molebogeng X; Wilkinson, Robert J; Boulle, Andrew; Glynn, Judith R; Fielding, Katherine; van Cutsem, Gilles; Wilkinson, Katalin A; Goliath, Rene; Mathee, Shaheed; Goemaere, Eric; Maartens, Gary
Journal:
Lancet
Abstract:
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.
Publisher:
The Lancet
Issue Date:
13-May-2014
URI:
http://hdl.handle.net/10144/322390
DOI:
10.1016/S0140-6736(14)60162-8
PubMed ID:
24835842
Language:
en
ISSN:
1474-547X
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorRangaka, Molebogeng Xen_GB
dc.contributor.authorWilkinson, Robert Jen_GB
dc.contributor.authorBoulle, Andrewen_GB
dc.contributor.authorGlynn, Judith Ren_GB
dc.contributor.authorFielding, Katherineen_GB
dc.contributor.authorvan Cutsem, Gillesen_GB
dc.contributor.authorWilkinson, Katalin Aen_GB
dc.contributor.authorGoliath, Reneen_GB
dc.contributor.authorMathee, Shaheeden_GB
dc.contributor.authorGoemaere, Ericen_GB
dc.contributor.authorMaartens, Garyen_GB
dc.date.accessioned2014-07-03T22:34:34Z-
dc.date.available2014-07-03T22:34:34Z-
dc.date.issued2014-05-13-
dc.identifier.citationIsoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. 2014: Lanceten_GB
dc.identifier.issn1474-547X-
dc.identifier.pmid24835842-
dc.identifier.doi10.1016/S0140-6736(14)60162-8-
dc.identifier.urihttp://hdl.handle.net/10144/322390-
dc.description.abstractAntiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.en_GB
dc.languageENG-
dc.language.isoenen
dc.publisherThe Lanceten_GB
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment.en_GB
dc.titleIsoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.en
dc.identifier.journalLanceten_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.